{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:35:25Z","timestamp":1768437325030,"version":"3.49.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The rapidly developed CAR-T cell therapy has a unique profile of side effects, which perhaps has not been totally realized and understood, especially the late-phase toxicity. CMV is prevalent world-wide and establishes a life-long latency infection. It can lead to life-threatening complications in immunocompromised host, and little is known about CMV disease in patients after CAR-T cell therapy. Here, we report a patient who developed possible CMV-pneumonia three months after anti-CD19 and anti-CD22 CAR-T cell therapy for relapsed B-ALL, contributing to the understanding of severe side-effects mediated by virus infection or reactivation in patients receiving CAR-T cell infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 21-year old male patient with relapsed B-ALL received anti-CD19\/22 CAR-T cell therapy, and achieved complete remission 2 weeks after the infusion. However, three months later, the patient was hospitalized again with a 10-day history of fever and cough and a 3-day history of palpitations and chest tightness. He was diagnosed with possible CMV pneumonia. Under treatment with antiviral medicine (ganciclovir\/penciclovir), intravenous gamma globulin and methylprednisolone and the use of BiPAP ventilator, his symptoms improved, but after removing penciclovir his symptoms went out of control, and the patient died of respiratory failure 22 days after admission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CMV infection\/reactivation can occur in patients long after receiving anti-CD19\/22 CAR-T cell therapy, and induce fatal pneumonia, which reminds us of the late side effects associated with immunosuppression after CAR-T cell infusion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1226148","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:38:25Z","timestamp":1696264705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiali","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/08830189309061702","article-title":"Chimeric T cell receptor-immunoglobulin molecules: function and applications","volume":"10","author":"Hedrick","year":"1993","journal-title":"Int Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","article-title":"Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma","volume":"7","author":"Wei","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2873-8","article-title":"Baseline antibody level may help predict the risk of active human cytomegalovirus infection in a HCMV seropositive population","volume":"36","author":"Li","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0022-2015","article-title":"Cytomegalovirus","volume":"4","author":"Dioverti","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms20112666","article-title":"Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy","volume":"20","author":"Cho","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B11","article-title":"Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation","volume":"90","author":"Ng","year":"2005","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1907","article-title":"Review of cytomegalovirus coinfection in HIV-infected individuals in Africa","volume":"27","author":"Gr\u00f8nborg","year":"2017","journal-title":"Rev Med Virol"},{"key":"B13","first-page":"65","article-title":"Cytomegalovirus infection in non-transplant patients with hematologic neoplasms: a case series","volume":"34","author":"Chang","year":"2011","journal-title":"Chang Gung Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.10.002","article-title":"[Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia (2016)]","volume":"37","year":"2016","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","article-title":"Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: A case report","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological Malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21294","article-title":"Cytomegalovirus pneumonia in patients with lymphoma","volume":"104","author":"Chemaly","year":"2005","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01670-06","article-title":"Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer","volume":"45","author":"Han","year":"2007","journal-title":"J Clin Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1086\/318721","article-title":"Cytomegalovirus pneumonia in adults with leukemia: an emerging problem","volume":"32","author":"Nguyen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3143","article-title":"Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products","volume":"101","author":"Nichols","year":"2003","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect Drug Resist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2447-3","article-title":"Antiviral prophylaxis in patients with solid tumours and haematological Malignancies\u2013update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"94","author":"Sandherr","year":"2015","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2453","article-title":"Cytomegalovirus infection in hematologic Malignancy settings other than the allogeneic transplant","volume":"36","author":"Marchesi","year":"2018","journal-title":"Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/383040","article-title":"A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients","volume":"189","author":"Mattes","year":"2004","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1226148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:38:32Z","timestamp":1696264712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1226148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2023.1226148"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1226148","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"article-number":"1226148"}}